Using Patient-Friendly Composite Endpoints to Measure the Success of Acute Migraine Medications : 4th Annual Migraine Meeting, Budapest, October 2004: Proceedings. Supplement Issue: European Neurology 2005, Vol. 53, Suppl. 1

Title from ebook title screen (viewed July 8, 2005) Contents......Page 4 Introduction......Page 5 Reference......Page 6 Recognition and Management of Migraine......Page 7 What Are Patients’ Expectations of Migraine Management?......Page 8 Which Treatment Outcomes Are Associated with Satisfaction?......Page 9 How Can Patients’ Expectations Be Met?......Page 11 References......Page 13 Migraine and Allodynia – the Clinical Picture......Page 14 Central Sensitisation......Page 15 Central Sensitisation and the Trigeminocervical Complex – Explaining Neck Pain......Page 16 Disinhibitory Sensitisation – Disordered Modulation of Trigeminovascular Afferent Signals......Page 18 References......Page 19 Introduction......Page 21 Clinical Trial Evidence in Favor of Early Treatment: A Critical Appraisal......Page 22 Conclusions......Page 24 References......Page 25 Introduction......Page 26 Results from Meta Analysis with Different Endpoints......Page 27 Incorporating Tolerability with Efficacy: Sustained Pain Free with No Adverse Events......Page 29 The Basis of Differences between Triptans......Page 30 References......Page 32 Introduction......Page 33 Short-Term Controlled Clinical Trials......Page 34 Long-Term Open-Label Clinical Trials......Page 35 Early Intervention post hoc Analyses......Page 36 References......Page 37 Abstract......Page 38 Randomized Controlled Trials vs. Postmarketing Surveillance Studies......Page 39 Randomized Controlled Trials vs. Postmarketing Surveillance Studies of Triptans......Page 40 Spanish and German Postmarketing Surveillance Studies......Page 41 Conclusion......Page 43 References......Page 44 Introduction......Page 45 Study Design......Page 46 Patients......Page 47 Secondary Efficacy Endpoints......Page 48 Safety and Tolerability......Page 49 Discussion......Page 50 Acknowledgments......Page 51 References......Page 52